| MAOI | monoamine oxidase inhibitor |
|---|---|
| MAO | 1) MonoAmine Oxidase 2) Maximal Acid Output |
| MAOI | MonoAmine Oxidase Inhibitors |
| MAO | Master of the Art of Obstetrics; maximal acid output; monoamine oxidase |
| MAOA | monoamine oxidase A |
| MAOI | Monoamine oxidase inhibitor |
|---|---|
| MAO | Catechol-0-methyltransferase and monoamine oxidase |
| MAO | Monoamine Oxidase |
| MAO | Monoamine oxidase activity |
| MAO A | Monoamine oxidase type A |
Nadsonieae
| monoamine oxidase inhibitor | <pharmacology> A drug that interferes with the action of monoamine oxidase, slowing the breakdown of certain neurotransmitters. Used in the treatment of depression. Monoamine oxidase inhibitors are a group of antidepressant drugs that prevent the activity of the enzyme monoamine oxidase in the central nervous system (brain) thus affecting mood. The use of these medications is often restricted due to their severe side effects and drug (and food) interactions. Examples include isocarboxazid, pargyline, selegiline, furazolidone and phenelzine. Acronym: MAOI (26 Mar 1998) |
|---|---|
| monoamine oxidase inhibitors | A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. Although mao inhibitors are probably as effective as tricyclic antidepressants in the treatment of major depression, the complex, sometimes severe, and often unpredictable interactions between mao inhibitors and many other drugs and food-derived amines make their medical use difficult and potentially hazardous. (12 Dec 1998) |
| monoamine oxidase | <enzyme> Catalysing breakdown of several biogenic amines, such as serotonin, adrenaline, noradrenaline, dopamine. (18 Nov 1997) |
|---|---|
| monoamine | <biochemistry> A molecule containing one amine group. Synonym: monamine. (05 Mar 2000) |
| monoamine neurotransmitters | A group of naturally occurring amines derived by enzymatic decarboxylation of the natural amino acids. Many have powerful physiological effects (e.g., histamine, serotonin, epinephrine, tyramine). Those derived from aromatic amino acids, and also their synthetic analogs (e.g., amphetamine), are of use in pharmacology. (12 Dec 1998) |
| a1-trypsin inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| aldose reductase inhibitor | <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. (09 Oct 1997) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| aromatase inhibitor | Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens. (05 Mar 2000) |
| beta-lactamase inhibitor | <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance. (05 Mar 2000) |
| Bowman-Birk inhibitor | A polypeptide that will inhibit both trypsin and chymotrypsin. (05 Mar 2000) |
| C1 esterase inhibitor | An a2-neuraminoglycoprotein that inhibits the enzymatic activity of C1 esterase, the activated first component of complement. A deficiency of this inhibitor results in a lack of inhibition of C1r and C1s leading to uncontrolled activation of the complement cascade and oedema. (05 Mar 2000) |
| carbonate dehydratase inhibitor | An agent, usually chemically related to the sulfonamides, that inhibits the activity of carbonate dehydratase, producing a general decrease in the formation of H2CO3 in the tissues. See: acetazolamide, dichlorphenamide. Synonym: carbonic anhydrase inhibitor. (05 Mar 2000) |
| carbonic acid inhibitor | <pharmacology> A group of diuretic medications which act to inhibit the enzyme carbonic anhydrase to create a metabolic acidosis. Many of these medications are used in the treatment of glaucoma. (27 Sep 1997) |
| carbonic anhydrase inhibitor | <pharmacology> A group of medications (sulphonamide drugs) which inhibit the enzyme carbonic anhydrase. These medications are used in the treatment of glaucoma. Examples include acetazolamide, dichlorphenamide and methazolamide. (27 Sep 1997) |
| mammary derived growth inhibitor | Fatty acid binding protein that inhibits proliferation of mammary carcinoma cells. (18 Nov 1997) |
Synonyms : Monoamine Oxidase Inhibitor, RIMA (Reversible Inhibitor of Monoamine Oxidase A), Reversible Inhibitor of Monoamine Oxidase, Inhibitor, Monoamine Oxidase, Inhibitors, MAO, Inhibitors, Monoamine Oxidase
| monoamine oxidase inhibitor |
any of a group of antidepressant drugs that inhibit the action of monoamine oxidase in the brain and so allow monoamines to accumulate
출처: wordnet.princeton.edu/perl/webwn
|
|---|---|
| monoamine oxidase inhibitor |
Monoamine oxidase inhibitors (MAOIs) are a class of antidepressant drugs prescribed for the treatment of depression. Due to potentially serious dietary and drug interactions they are used less frequently than other classes of antidepressant drugs (for example tricyclic antidepressants and selective serotonin reuptake inhibitors). However, in some cases where patients are unresponsive to other treatments they are tried, often with a marked success. ...
출처: en.wikipedia.org/wiki/Monoamine_oxidase_inhibitor
|
| monoamine oxidase inhibitor |
(MAOI): Substances that inactivate the enzyme monoamine oxidase which regulates certain transmitter chemicals between nerves. These compounds include certain types of antidepressants and also insecticides containing amitraz (such as Mitaban and Preventic collars).
출처: www.peteducation.com/dict_alpha_listing.cfm
|
| monoamine oxidase inhibitor |
A drug that interferes with the action of monoamine oxidase, slowing the breakdown of certain neurotransmitters. Used in the treatment of depression.
출처: www.alz.org/Resources/Glossary.asp
|
| monoamine oxidase inhibitor |
an enzyme that breaks down biogenic amines (neurotransmitters). Inhibition of this enzyme by certain antidepressant drugs (MAO inhibitors) may relieve a patient's depression.
출처: www2.med.umich.edu/psychiatry/umdc/defquery.cfm
|
| monoamine oxidase inhibitor | any of a group of antidepressant drugs that inhibit the action of monoamine oxidase in the brain and so allow monoamines to accumulate |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|